Scientists have reported a breakthrough in treating genetic deafness, with an experimental gene therapy successfully restoring hearing in all 10 patients involved in a clinical trial.
The treatment involves a single injection into the inner ear, where researchers deliver a healthy version of a key gene responsible for hearing. Patients began showing measurable improvements within weeks, with many responding to sounds in less than a month.
The therapy specifically targets mutations in the OTOF gene, which plays a crucial role in transmitting sound signals from the inner ear to the brain. Defects in this gene can lead to a rare form of inherited deafness.
The trial included both young children and young adults, all of whom experienced significant improvements in hearing ability. Many patients progressed to the point where they could clearly understand speech, marking a substantial recovery compared to their condition before treatment.
Researchers observed that younger patients showed the most dramatic improvements, although older participants also benefited meaningfully from the therapy.
Unlike traditional solutions such as hearing aids or cochlear implants, which either amplify sound or bypass damaged structures, this approach directly addresses the underlying genetic cause of hearing loss.
Experts believe this advancement could open the door to treating a wider range of hereditary hearing conditions in the future, making it one of the most promising developments in hearing restoration to date.
